Literature DB >> 20609987

Antiretroviral therapy and management of HIV infection.

Paul A Volberding1, Steven G Deeks.   

Abstract

Antiretroviral therapy of HIV infection has changed a uniformly fatal into a potentially chronic disease. There are now 17 drugs in common use for HIV treatment. Patients who can access and adhere to combination therapy should be able to achieve durable, potentially lifelong suppression of HIV replication. Despite the unquestioned success of antiretroviral therapy, limitations persist. Treatment success needs strict lifelong drug adherence. Although the widely used drugs are generally well tolerated, most have some short-term toxic effects and all have the potential for both known and unknown long-term toxic effects. Drug and administration costs limit treatment in resource-poor regions, and are a growing concern even in resource rich settings. Finally, complete or near complete control of viral replication does not fully restore health. Long-term treated patients who are on an otherwise effective regimen often show persistent immune dysfunction and have higher than expected risk for various non-AIDS-related complications, including heart, bone, liver, kidney, and neurocognitive diseases. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20609987     DOI: 10.1016/S0140-6736(10)60676-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  164 in total

1.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

2.  Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

Authors:  Jenna A Rhoades; Yuri K Peterson; Hao-Jie Zhu; David I Appel; Charles A Peloquin; John S Markowitz
Journal:  Pharm Res       Date:  2011-12-09       Impact factor: 4.200

3.  HIV status is an independent risk factor for reporting lower urinary tract symptoms.

Authors:  Benjamin N Breyer; Stephen K Van den Eeden; Michael A Horberg; Michael L Eisenberg; Donna Y Deng; James F Smith; Alan W Shindel
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

4.  Metabolomics reveals differential levels of oral metabolites in HIV-infected patients: toward novel diagnostic targets.

Authors:  Mahmoud A Ghannoum; Pranab K Mukherjee; Richard J Jurevic; Mauricio Retuerto; Robert E Brown; Masoumeh Sikaroodi; Jennifer Webster-Cyriaque; Patrick M Gillevet
Journal:  OMICS       Date:  2011-07-13

5.  Reproductive decisions of couples living with HIV in Malawi: what can we learn for future policy and research studies?

Authors:  B Chimphamba Gombachika; E Chirwa; A Malata; J Sundby; H Fjeld
Journal:  Malawi Med J       Date:  2013-09       Impact factor: 0.875

6.  HIV: Antibodies advance the search for a cure.

Authors:  Louis J Picker; Steven G Deeks
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

7.  Overcoming Barriers to HIV Treatment Adherence: A Brief Cognitive Behavioral Intervention for HIV-Positive Adults on Antiretroviral Treatment.

Authors:  David Olem; Kelly M Sharp; Jonelle M Taylor; Mallory O Johnson
Journal:  Cogn Behav Pract       Date:  2014-05-01

8.  A Novel Integrated Cognitive-Behavioral Therapy for Anxiety and Medication Adherence Among Persons Living With HIV/AIDS.

Authors:  Charles P Brandt; Daniel J Paulus; Monica Garza; Chad Lemaire; Peter J Norton; Michael J Zvolensky
Journal:  Cogn Behav Pract       Date:  2017-03-02

9.  Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Authors:  Ighovwerha Ofotokun; Lumine H Na; Raphael J Landovitz; Heather J Ribaudo; Grace A McComsey; Catherine Godfrey; Francesca Aweeka; Susan E Cohn; Manish Sagar; Daniel R Kuritzkes; Todd T Brown; Kristine B Patterson; Michael F Para; Randi Y Leavitt; Angelina Villasis-Keever; Bryan P Baugh; Jeffrey L Lennox; Judith S Currier
Journal:  Clin Infect Dis       Date:  2015-03-12       Impact factor: 9.079

10.  8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes.

Authors:  Maria Brandmann; Uwe Nehls; Ralf Dringen
Journal:  Neurochem Res       Date:  2013-10-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.